Neutral
Last updated: 2026-05-21 19:46:03 ET
The results bring Lilly one step closer to filing for approval of the injection, retatrutide, which works differently from existing injections and pills.
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
The weight loss pill had a strong U.S. launch this year, and Novo believes that will be replicated in other markets around the world.
Earlier this week, Eli Lilly reported detailed late-phase obesity trial results showing long-term weight maintenance with injectable Zepbound and oral...
Eli Lilly (LLY) stock is back in focus after the company reported a very strong Q1, raised its full year revenue and earnings guidance, and released n...
Pharma stocks are gaining momentum as obesity drugs, oncology therapies and biotech innovation boost investor optimism.
MBX Biosciences (NasdaqGS:MBX) reported encouraging preliminary Phase 1 data for its lead obesity candidate, MBX 4291, with early weight loss signals ...
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE